In Brief
Refine Search
Biotechnology
Japanese drugmaker Eisai today that the humanized antisoluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) has been launched in South Korea. 28 November 2024
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Thursday’s trading wiped more than 43% off the value of Talaris Therapeutics, a US cell therapy firm developing treatments in solid organ transplantation and severe immune and blood disorders. 21 October 2022
Biotechnology
US clinical-stage biotech Minerva Neurosciences (Nasdaq: NERV) has recently received a refusal to file letter from the Food and Drug Administration (FDA) regarding its new drug application (NDA) for roluperidone, which was filed in August, for the treatment of negative symptoms in patients with schizophrenia, is yet another obstacle to the drug’s development. 21 October 2022
Biotechnology
Belgian company Rewind Therapeutics, which is developing first-in-class treatments for demyelination-associated diseases, has named Irene Knuesel its new chief scientific officer (CSO). 21 October 2022
Biotechnology
In the first three quarters of the year, with investment activity accelerating in the three months leading to August 31, UK-based life sciences and biotech companies raised some £1.5 billion ($1.67 billion) in equity finance. 21 October 2022
Biotechnology
Shares in Parisian immuno-oncology specialist OSE Immunotherapeutics rose by around a third on Friday morning, after the firm provided an update on its neoepitope cancer vaccine Tedopi. 21 October 2022
Biotechnology
Following a Series A financing of $27 million a year ago, Singapore-based AUM Biosciences has entered into an agreement to merge with Mountain Crest Acquisition Corp, a publicly-traded special purpose acquisition company (SPAC). 21 October 2022
Pharmaceutical
USA-based CNS specialist Corium and Gurnet Point Capital have announced the acquisition of their manufacturing business and a $100 million equity investment by Webster Equity Partners. 21 October 2022
Biotechnology
Swiss pharma giant Roche has become the latest large biopharma company to team up with Austrian arenaviral technology firm Hookipa Pharma. 20 October 2022
Biotechnology
Data on Incyte’s Opzelura (ruxolitinib) cream from the pivotal Phase III TRuE-V clinical trial program have been published in The New England Journal of Medicine (NEJM). 20 October 2022
Biotechnology
While there has been a dearth mega-billion M&A activity in the pharma sector this year, smaller deals are coming through, now with US pharma major AbbVie announcing its second acquisition this year. 20 October 2022
Pharmaceutical
Japanese gastroenterology giant Takeda has inked a deal with German firms Zedira and Dr. Falk Pharma for the development of a celiac disease candidate, TAK-227. 20 October 2022
Generics
Swiss pharma giant Novartis has entered into a voluntary licensing agreement for its chronic myeloid leukemia (CML) drug with the Medicines Patent Pool (MPP), agreeing to the production of generics in low-and-middle income countries. 20 October 2022
Biotechnology
Bristol Myers Squibb has presented data that reinforces the benefits of its immuno-oncology blockbuster Opdivo (nivolumab) in the earlier stages of melanoma. 20 October 2022
Pharmaceutical
The US Food and Drug Administration’s (FDA) Obstetrics, Reproduction and Urologic Advisory Committee yesterday voted to recommend that the FDA pursue withdrawal of approval of privately-held Swiss drugmaker Covis Pharma’s Makena (hydroxyprogesterone caproate injection), the only FDA-approved treatment to reduce the risk of preterm birth in pregnant women who have had a prior spontaneous preterm birth. 20 October 2022
Biotechnology
An alternative to mRNA-based coronavirus vaccines has received an Emergency Use Authorization in the USA, providing a new option for a first booster dose. 20 October 2022
Biotechnology
The European Medicines Agency’s (EMA) human medicines committee (CHMP) has recommended extending the use of Comirnaty and Spikevax targeting the original strain of SARS-CoV-2. 20 October 2022
Pharmaceutical
The US Food and Drug Administration (FDA) has announced the Advancing Real-World Evidence (RWE) Program. 20 October 2022
Pharmaceutical
A stark warning on UK access to innovation has been issued by the Association of the British Pharmaceutical Industry (ABPI). 20 October 2022
Biotechnology
US messenger RNA (mRNA) Moderna today announced new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214, demonstrating its superiority of the biotech’s original COVID-19 vaccine Spikevax. 19 October 2022
Pharmaceutical
The recent European Commission’s (EC) approval of Eli Lilly’s (NYSE: LLY) Mounjaro (tirzepatide) for treating type 2 diabetes (T2D) is of paramount interest, and not only for T2D patients, as it could address vital unmet needs for other GIP/GLP-1 receptor agonist–treated diseases, including obesity. 19 October 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze